MedPath

Estetrol Therapy in Sjögren’s Syndrome: An Open Proof of Concept

Completed
Conditions
Primary Sjögren’s syndrome
Registration Number
NL-OMON22190
Lead Sponsor
EMCInvestigator-initiated study
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

1. Have the capacity to understand and willing to sign an informed consent form.

2. Fulfill American-European consensus criteria for primary Sjögren’s syndrome.

Exclusion Criteria

1. Have a history of alcohol or substance abuse within the preceding 6 months.

2. Have a history of malignancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary endpoint consists of a composite endpoint concerning meaningful improvement across 2 or 3 Sjögren’s syndrome disease domains: oral, ocular and laboratory test
Secondary Outcome Measures
NameTimeMethod
Secondary endpoints include: <br /><br>- improvement in quantitative levels of SSA and/or SSB<br /><br>- decrease in pilocarpine use during treatment<br /><br>- improvement in results of SF36
© Copyright 2025. All Rights Reserved by MedPath